Pacific Biosciences of California, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Pacific Biosciences of California, Inc. (PACB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.90 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-25
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $5.97, a 55.06% increase year-over-year.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $3.85.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.90, a 35.71% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.40, a 80.87% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.32, a 23.44% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.93, a 67.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2025-12-31 | $0.90 10-K · filed 2026-02-25 | ||
| 2024-12-31 | $1.40 10-K · filed 2026-02-25 | ||
| 2023-12-31 | $7.32 10-K · filed 2026-02-25 | ||
| 2022-12-31 | $5.93 10-K · filed 2025-03-17 | ||
| 2021-12-31 | $18.36 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $5.97 10-Q · filed 2021-11-05 | $15.63 10-Q · filed 2021-11-05 | |
| 2020-12-31 | $4.14 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $3.85 10-Q · filed 2021-11-05 | $3.82 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |